Business Wire

MI-EATON

25.8.2021 12:32:04 CEST | Business Wire | Press release

Share
Eaton’s Vehicle Group Unveils Complete Range of Differentials for Electrified Vehicles

Power management company Eaton today announced its Vehicle Group has launched an extensive lineup of specialized differentials for electrified vehicles with comparable performance to traditional internal combustion engine (ICE) vehicles. The passenger vehicle market is increasingly transitioning to electrified vehicles (EVs), and Eaton has the expertise and experience to provide the solution EV manufacturers need.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005114/en/

Eaton’s Traction Control family of differentials can provide improved traction in adverse conditions, such as snow and mud, and improved stability while trailering. As a global supplier, Eaton has extensive knowledge of vehicle dynamics and safety standards, as well as decades of experience working with global automotive manufacturers to integrate differentials into new vehicle platforms. Eaton has been supplying differentials to the EV market since 2015.

“Eaton conducts a total system analysis, using state-of-the-art tools and in-house know-how, to design a differential for electrified vehicles optimized for efficiency, reliability and manufacturing,” said Brent Pawlak, business unit director, Eaton’s Vehicle Group. “We also can partner with an OEM to design and develop a differential to specifications and requirements, including torque levels, duty cycles, fatigue and size requirements, as EVs often require compact components and unique torque requirements that can be integrated into electrified drivetrains.”

Eaton offers a full range of differentials for electrified vehicles, including automatic limited-slip, automatic locking and electronic selectable locking differentials. Each differential is highly engineered, tested and validated for a variety of traction control applications. Performance is verified at Eaton’s Proving Ground testing complex in Marshall, Michigan, which is home to more than 600 acres of testing facilities and tracks.

Eaton’s Traction Control solutions include:

  • Truetrac® – Helical-gear limited-slip differential maximizes wheel traction and enhances driving and handling characteristics. Easily integrated into compact packaging spaces, with high power density capacity.
  • ELocker® – Allows for maximum driveline flexibility. Users can switch from a fully open to a fully locked axle at the touch of a button, or it can be integrated into the vehicle (auto-locking). High torque capacity and range, with compact designs for EV applications.
  • IntelliTrac™ – Smart electronically controlled, limited-slip differential is fully integrated to the vehicle to provide instant response and optimized vehicle performance at any speed or traction condition.
  • MLocker® – Automatic, mechanical locking differential which provides drivers best-in-class traction without the need for buttons, shift knobs or other driver intervention. Improves towing and off-road performance with low integration cost.
  • Posi® – Limited slip differential which automatically prevents wheel slip before it can get started. Easily integrates into most axle designs and can be tuned for application requirements.
  • Open – Compact open differential which allows cost-effective solution for managing torque between left and right wheels.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye